FDA plan for rare neurodegenerative diseases

Friday 15 July 2022


The US Food and Drug Administration has launched a plan to support the development of new medicines for rare neurodegenerative diseases including amyotrophic lateral sclerosis, a progressive disease that affects nerves in the brain and spinal cord, causing loss of muscle control. The plan has been developed in line with new US legislation, the Accelerating Access to Critical Therapies for ALS Act that took effect on 23 December 2021.